{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:23:21Z","timestamp":1794961401712,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The role of JAK inhibitors in immune-mediated adverse events was not included in the EULAR 2021 guidance on the management of rheumatic immune-related adverse events (irAE) from checkpoint inhibitors or the society of immunotherapy of cancer guidelines on this topic. We aim to describe the role of JAK inhibitors for the management of immune-mediated adverse events with a review of case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed, EMBASE and MEDLINE searches were performed from inception until 25 May 2025 for case reports\/series of the use of JAK inhibitors to treat checkpoint inhibitor-induced immune adverse events. Five EMA-licensed JAK inhibitors (tofacitinib, baritinib, upadacitinib, filgotinib and ruxolitinib) were included in addition to peficitinib. The 11 FDA-approved checkpoint inhibitors were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Published case reports, case series and cohort data included 104 patients. Most patients received tofacitinib (82%). Pembrolizumab monotherapy represented the most common immune checkpoint inhibitor. The commonest cancers were lung (20%), followed by gastric (17%) and metastatic melanoma (16%). The indication for JAK inhibitor therapy for irAEs was predominantly myocarditis (70%), followed by myositis (33%) and hepatitis (24%). Tumour progression was observed in 38% of patients, with 14% remaining in remission. Across all patients, 4% died due to progression of their cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JAK inhibitors are emerging as a promising option for the treatment of immune checkpoint inhibitor-related toxicities. The currently published evidence, primarily from case reports and case series, suggests they have efficacy, particularly in patients who have failed to respond to other cytokine inhibition strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf356","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T07:34:12Z","timestamp":1751182452000},"page":"5641-5646","source":"Crossref","is-referenced-by-count":14,"title":["The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-6528","authenticated-orcid":false,"given":"Deepak","family":"Nagra","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]},{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Song","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Odia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]},{"name":"Rheumatology Department, King\u2019s College Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Mahto","sequence":"additional","affiliation":[{"name":"Rheumatology Department, King\u2019s College Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamith","family":"Rosa","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Kasavkar","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-6603","authenticated-orcid":false,"given":"Maryam A","family":"Adas","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark D","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-1015","authenticated-orcid":false,"given":"Tim","family":"Blake","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwalik","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-4116","authenticated-orcid":false,"given":"Nicola","family":"Gullick","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry & Warwickshire , Coventry,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James B","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Disease, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2025110820494796400_keaf356-B1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025110820494796400_keaf356-B2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820494796400_keaf356-B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025110820494796400_keaf356-B4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"2025110820494796400_keaf356-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J Clin Med"},{"key":"2025110820494796400_keaf356-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025110820494796400_keaf356-B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025110820494796400_keaf356-B8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025110820494796400_keaf356-B9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"2025110820494796400_keaf356-B10","doi-asserted-by":"crossref","first-page":"e24380","DOI":"10.1016\/j.heliyon.2024.e24380","article-title":"Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients\u2014a case report and review of the literature","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"2025110820494796400_keaf356-B11","article-title":"Can we treat anti-PD1 induced psoriasis in patients with active cancer with biologic therapy? Report of three cases","author":"Rodr\u00edguez-Jim\u00e9nez","year":"2023","journal-title":"Open Access J Eur Acad Dermatol Venerol"},{"key":"2025110820494796400_keaf356-B12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"2025110820494796400_keaf356-B13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","article-title":"Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"2025110820494796400_keaf356-B14","doi-asserted-by":"crossref","first-page":"sfae127","DOI":"10.1093\/ckj\/sfae127","article-title":"Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis","volume":"17","author":"Shivaraj","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025110820494796400_keaf356-B15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025110820494796400_keaf356-B16","first-page":"1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: the first reported cases","author":"Liu","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2025110820494796400_keaf356-B17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmjgast-2022-000989","article-title":"Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report","volume":"9","author":"Holmstroem","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2025110820494796400_keaf356-B18","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"key":"2025110820494796400_keaf356-B19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"key":"2025110820494796400_keaf356-B20","doi-asserted-by":"crossref","first-page":"e04459","DOI":"10.1002\/ccr3.4459","article-title":"Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir","volume":"9","author":"Oda","year":"2021","journal-title":"Clin Case Rep"},{"key":"2025110820494796400_keaf356-B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/rmdopen-2022-002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","journal-title":"RMD Open"},{"key":"2025110820494796400_keaf356-B22","first-page":"e70032","article-title":"JAK inhibitor upadacitinib induces remission in refractory immune-related colitis triggered by CTLA-4 and PD-1 inhibitor combination therapy in malignant pleural mesothelioma: a case report","volume":"7","author":"Kono","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"2025110820494796400_keaf356-B23","first-page":"1","article-title":"Novel treatment of immune checkpoint inhibitor fulminant myocarditis with resolution of cardiogenic shock","volume":"79","author":"Zackary Tushak","year":"2022","journal-title":"JACC"},{"key":"2025110820494796400_keaf356-B24","doi-asserted-by":"crossref","first-page":"944013","DOI":"10.3389\/fimmu.2022.944013","article-title":"Case Report: treatment for steroid-refractory immune-related myocarditis with tofacitinib","volume":"13","author":"Xing","year":"2022","journal-title":"Front Immunol"},{"key":"2025110820494796400_keaf356-B25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025110820494796400_keaf356-B26","doi-asserted-by":"crossref","first-page":"113319","DOI":"10.1016\/j.ejca.2023.113319","article-title":"Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms","volume":"194","author":"Abitbol","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025110820494796400_keaf356-B27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjcard.2023.04.037","article-title":"Immune checkpoint inhibitor rechallenge in a patient with previous fulminant myocarditis","volume":"199","author":"Menachery","year":"2023","journal-title":"Am J Cardiol"},{"key":"2025110820494796400_keaf356-B28","article-title":"Abatacept and ruxolitinib for pembrolizumab-induced myocarditis with cardiogenic shock refractory to high-dose steroids","author":"Mordechai Grabie","year":"2024","journal-title":"JACC"},{"key":"2025110820494796400_keaf356-B29","doi-asserted-by":"crossref","first-page":"114027","DOI":"10.1016\/j.ejca.2024.114027","article-title":"Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome","volume":"202","author":"Byer","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025110820494796400_keaf356-B30","doi-asserted-by":"crossref","first-page":"ytaf019","DOI":"10.1093\/ehjcr\/ytaf019","article-title":"Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report","volume":"9","author":"Wadden","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"2025110820494796400_keaf356-B31","first-page":"1","article-title":"Overlapping obstacles: a case of immune checkpoint inhibitor overlap syndrome","volume":"85","author":"Georgia","year":"2025","journal-title":"JACC"},{"key":"2025110820494796400_keaf356-B32","first-page":"1","article-title":"The triple M affair\u2014a case of myocarditis-myositis-myasthenia gravis overlap syndrome from immune checkpoint inhibitor","volume":"85","author":"Hafsa Syeda","year":"2025","journal-title":"JACC"},{"key":"2025110820494796400_keaf356-B33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2025.02.004","article-title":"Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown","volume":"7","author":"Bailly","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2025110820494796400_keaf356-B34","doi-asserted-by":"crossref","first-page":"770631","DOI":"10.3389\/fphar.2021.770631","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025110820494796400_keaf356-B35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.cgh.2023.12.011","article-title":"Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis","volume":"22","author":"Wang","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2025110820494796400_keaf356-B36","doi-asserted-by":"crossref","first-page":"1212432","DOI":"10.3389\/fimmu.2023.1212432","article-title":"Case Report: a severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib","volume":"14","author":"Sweep","year":"2023","journal-title":"Front Immunol"},{"key":"2025110820494796400_keaf356-B37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12328-023-01826-6","article-title":"Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways","volume":"16","author":"Sleiman","year":"2023","journal-title":"Clin J Gastroenterol"},{"key":"2025110820494796400_keaf356-B38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.gastro.2024.09.034","article-title":"Immune checkpoint inhibitor-induced colitis","volume":"168","author":"S Thomas","year":"2025","journal-title":"Gastroenterology"},{"key":"2025110820494796400_keaf356-B39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025110820494796400_keaf356-B40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11481-021-10026-3","article-title":"Immune-related cerebellar ataxia: a rare adverse effect of checkpoint inhibitor therapy","volume":"17","author":"Sebbag","year":"2022","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"2025110820494796400_keaf356-B41","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s12311-024-01727-5","article-title":"Immune checkpoint inhibitor-related cerebellar toxicity: clinical features and comparison with paraneoplastic cerebellar ataxia","volume":"23","author":"Dentoni","year":"2024","journal-title":"Cerebellum"},{"key":"2025110820494796400_keaf356-B42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2019.03.016","article-title":"Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib","volume":"113","author":"Chen","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025110820494796400_keaf356-B43","doi-asserted-by":"crossref","first-page":"107779","DOI":"10.1016\/j.lungcan.2024.107779","article-title":"A case of Toxic Epidermal Necrolysis secondary to combination Ipilimumab and Nivolumab therapy for Pleural Mesothelioma, successfully treated with Ruxolitinib","volume":"190","author":"Tabbakh","year":"2024","journal-title":"Lung Cancer"},{"key":"2025110820494796400_keaf356-B44","doi-asserted-by":"crossref","first-page":"2050313X231160926","DOI":"10.1177\/2050313X231160926","article-title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report","volume":"11","author":"Gresham","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2025110820494796400_keaf356-B45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mayocp.2023.11.014","article-title":"Generic tofacitinib-a more affordable JAK inhibitor","volume":"99","author":"Goll","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"2025110820494796400_keaf356-B46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110820494796400_keaf356-B47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820494796400_keaf356-B48","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"2025110820494796400_keaf356-B49","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br J Haematol"},{"key":"2025110820494796400_keaf356-B50","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf356\/63628280\/keaf356.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5641\/63628280\/keaf356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5641\/63628280\/keaf356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:49:58Z","timestamp":1762652998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5641\/8178594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf356","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,30]]}}}